Form 4: Azitra Director John Schroer Granted Stock Options

Azitra, Inc. director John R. Schroer was granted 3,003 stock options with an exercise price of $0.2968, vesting over 36 months.

Summary

• John R. Schroer, a director of Azitra, Inc. (AZTR), was granted 3,003 stock options.
• The options have an exercise price of $0.2968 per share.
• The grant date for these options was December 19, 2025.
• The options expire on December 19, 2035.
• 25% of the shares subject to the option vest immediately on the date of issuance (December 19, 2025).
• The remaining balance will vest in equal monthly installments over the subsequent 36 months of continuous service.
• Following this transaction, John R. Schroer beneficially owns 3,003 derivative securities directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine compensation event that aligns director incentives with company performance, but doesn't reflect new operational achievements or financial results. The potential for future dilution is a minor negative.

Positives

• The grant of stock options to a director aligns management incentives with shareholder interests.
• The exercise price of $0.2968 provides a clear benchmark for future stock performance.

Negatives

• No immediate cash inflow for the company from this grant, as the options were granted at $0.00.
• Potential future dilution if options are exercised.

Risks

• Future stock price may not exceed the exercise price, rendering the options worthless.
• Dilution of existing shareholder value if a significant number of options are exercised in the future.
• The vesting schedule requires continuous service, meaning the director must remain with the company to fully realize the benefit.

Future Outlook

The grant of stock options with a vesting schedule tied to continuous service suggests an intention to retain key leadership and align their long-term interests with the company's performance. The future value of these options is contingent on Azitra's stock price appreciating above the exercise price.

Industry Context

This is a standard equity compensation practice in the biotechnology and pharmaceutical industries, particularly for early-stage companies like Azitra, Inc., to incentivize directors and executives. Such grants are common for retaining talent and aligning their financial interests with long-term company growth and shareholder value creation.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across various industries, including biotech, to incentivize long-term commitment and performance.
• The vesting schedule (25% immediate, then monthly over 36 months) is a typical structure designed to encourage retention and sustained contribution, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their executives and board members, though the scale of grants would differ significantly based on company size and stage.
• An exercise price set at the market price on the grant date (implied by the $0.00 derivative price and the exercise price) is standard for incentive stock options.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also aligns director's interests with increasing shareholder value.
• Employees: No direct impact on general employees, but reflects standard executive compensation practices.

Next Steps

• Continued service by John R. Schroer to fulfill the vesting requirements of the options.
• Potential future exercise of options by John R. Schroer, subject to vesting and market conditions.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation. It does not contain any new operational, financial, or strategic information that would warrant a change in investment recommendation. The grant aligns the director's incentives with long-term shareholder value but is not a catalyst for immediate price movement.

Keywords

Azitra, AZTR, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Vesting Schedule, Insider Transaction